0
Signin
countryflagUS

18889881171

AAPL 167.04 -0.5714% MSFT 404.33 -1.8235% GOOG 157.46 0.3697% GOOGL 155.9725 0.3232% AMZN 179.17 -1.1639% NVDA 846.71 0.7568% META 501.8 1.544% TSLA 149.9 -3.5703% TSM 132.27 -4.8623% LLY 745.95 -0.642% V 271.36 -0.4877% AVGO 1258.99 -1.8431% JPM 181.25 0.6497% UNH 493.18 2.9625% NVO 122.75 -1.4294% WMT 59.27 -0.637% LVMUY 170.18 -0.3338% XOM 118.47 -0.1349% LVMHF 854.0 -0.4662% MA 454.7 -1.1865%

Allovir Inc

Healthcare US ALVR

0.7421USD
-0.0148(1.96%)

Last update at 2024-04-18T20:02:00Z

Day Range

0.730.77
LowHigh

52 Week Range

0.697.24
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -168.97500M -170.95500M -69.78400M -23.83900M -2.43000M
Minority interest - - - - -
Net income -168.71000M -171.96200M -68.38100M -21.77400M -2.43000M
Selling general administrative 52.33M 49.08M 21.65M 10.62M 3.03M
Selling and marketing expenses - - - - -
Gross profit - - - 0.17M 1.14M
Reconciled depreciation 0.72M 0.19M 0.07M 0.02M 0.00000M
Ebit -171.92500M -170.00700M -71.38200M -26.70100M -6.62700M
Ebitda -171.20200M -169.81800M -71.30900M -26.68200M -3.59600M
Depreciation and amortization 0.72M 0.19M 0.07M 0.02M 3.03M
Non operating income net other 2.23M -1.13700M 1.52M - -
Operating income -171.20200M -169.81800M -71.30900M -26.70100M -3.59600M
Other operating expenses 171.20M 169.82M 71.31M 26.87M 4.73M
Interest expense -2.95000M 0.95M 0.00000M 0.00000M 0.00000M
Tax provision -0.26500M 1.01M - - -
Interest income 1.88M 1.31M 1.33M 2.06M 0.06M
Net interest income 1.88M 1.31M 1.33M 2.06M 0.06M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.26500M 1.01M -1.40300M -2.06500M 1.17M
Total revenue 0.00000M 0.00000M 0.00000M 0.17M 1.14M
Total operating expenses 171.20M 169.82M 71.31M 26.87M 4.73M
Cost of revenue - - - - -
Total other income expense net 2.23M -1.13700M 1.52M 2.86M 1.11M
Discontinued operations - - - - -
Net income from continuing ops -168.71000M -171.96200M -69.78400M -23.83900M -2.43000M
Net income applicable to common shares -168.71000M -171.96200M -69.78400M -23.83900M -7.63700M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 277.08M 286.59M 370.82M 139.42M 25.32M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.26M 5.23M 4.99M 0.68M 0.05M
Total liab 52.56M 61.33M 17.76M 190.93M 55.94M
Total stockholder equity 224.52M 225.27M 353.06M -51.50300M -30.62200M
Deferred long term liab - - - - -
Other current liab 14.17M 22.90M 8.10M 5.41M 0.92M
Common stock 0.00900M 0.00700M 0.00700M - -
Capital stock 0.00900M 0.00700M 0.00700M 0.00000M 0.00000M
Retained earnings -465.77500M -297.06500M -125.10300M -55.31900M -31.48000M
Other liab - - - - -
Good will - - - - -
Other assets 1.46M 33.25M 9.50M - 0.00600M
Cash 106.09M 201.66M 122.66M 61.08M 22.20M
Cash and equivalents - - - - -
Total current liabilities 24.34M 37.85M 12.29M 9.11M 3.74M
Current deferred revenue - - - - 2.66M
Net debt -70.70500M -171.59500M -113.96900M -49.32500M -22.19900M
Short term debt 7.17M 6.59M 3.23M 3.07M -
Short long term debt - - - - -
Short long term debt total 35.39M 30.07M 8.69M 11.76M -
Other stockholder equity 690.75M 522.48M 107.45M -169.37900M -51.34600M
Property plant equipment 0.93M 1.55M 9.50M 12.11M -
Total current assets 243.05M 253.35M 361.32M 127.31M 25.31M
Long term investments - - - - -
Net tangible assets 224.52M 225.27M 353.06M -51.50300M -30.62200M
Short term investments 127.70M 46.46M 233.66M 64.99M 0.00000M
Net receivables 0.16M 0.05M 0.45M 0.56M 0.30M
Long term debt - - - - -
Inventory -0.15700M -0.05000M -0.45000M - 2.76M
Accounts payable 3.00M 8.36M 0.96M 0.63M 0.15M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.46800M -0.15500M -0.11200M 0.07M -
Additional paid in capital - - - - -
Common stock total equity 0.00900M 0.00700M 0.00700M - -
Preferred stock total equity - - - - -
Retained earnings total equity -465.77500M -297.06500M -125.10300M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.46M 1.95M 9.50M - 0.00600M
Deferred long term asset charges - - - - -
Non current assets total 34.03M 33.25M 9.50M 12.11M 0.00600M
Capital lease obligations 35.39M 30.07M 8.69M 11.76M 0.00000M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -80.47800M 186.01M -169.49700M -64.30500M -64.30500M
Change to liabilities -13.50100M 21.30M 2.73M 2.27M 3.26M
Total cashflows from investing activities -80.47800M 185.98M -169.49700M -64.64400M -64.64400M
Net borrowings - - - - -
Total cash from financing activities 126.96M 0.23M 291.98M 120.92M 22.87M
Change to operating activities -2.53800M -1.94300M -4.05500M -0.88200M -0.02800M
Net income -168.71000M -171.96200M -69.78400M -23.83900M -2.43000M
Change in cash -95.56900M 79.85M 61.58M 36.12M 24.82M
Begin period cash flow 202.51M 122.66M 61.08M 24.96M 0.14M
End period cash flow 106.94M 202.51M 122.66M 61.08M 24.96M
Total cash from operating activities -142.05200M -106.31900M -60.81100M -20.15500M 1.94M
Issuance of capital stock 126.42M 0.00000M 295.45M 121.25M 33.00M
Depreciation 0.72M 0.19M 0.07M 0.02M 3.03M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.10700M 0.40M 0.30M 0.00400M 0.17M
Sale purchase of stock 126.96M 0.23M 291.98M 0.00000M -10.00000M
Other cashflows from financing activities 0.54M 0.23M -3.47400M 120.92M 32.87M
Change to netincome 41.31M 43.98M 9.93M 2.27M 6.69M
Capital expenditures 0.10M 0.03M 0.23M 0.34M 0.34M
Change receivables -0.10700M 0.40M -0.18800M - -
Cash flows other operating -0.69600M -0.21800M -3.06700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -95.56900M 79.90M 61.67M - -
Change in working capital -16.14600M 19.35M -1.03100M 1.40M 3.41M
Stock based compensation 41.31M 43.98M 9.43M 2.89M 0.97M
Other non cash items 0.77M 0.93M 0.50M -0.62000M -3.03100M
Free cash flow -141.94800M -106.34500M -61.04600M -20.49400M 1.94M

Fundamentals

  • Previous Close 0.76
  • Market Cap81.52M
  • Volume525214
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-177.58600M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.17M
  • Diluted EPS TTM-1.67

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ALVR
Allovir Inc		 -0.0148 1.96% 0.74 - - - 1.30 -0.4099
NVO
Novo Nordisk A/S		 -1.78 1.43% 122.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.344 1.08% 122.81 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.38 0.10% 393.48 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 -1.042 1.18% 86.92 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Allovir Inc

1100 Winter Street, Waltham, MA, United States, 02451

Key Executives

Name Title Year Born
Mr. David L. Hallal Exec. Chairman 1966
Dr. Diana M. Brainard M.D. CEO & Director 1971
Mr. Vikas Sinha C.A., CPA, M.B.A. Pres, CFO & Director 1963
Dr. Jeroen van Beek Ph.D. Consultant 1964
Mr. Agustin Melian M.D. Advisor 1964
Mr. Brett R. Hagen Chief Accounting Officer 1973
Mr. Dana M. Alexander M.B.A. Sr. VP of Technical Operations 1976
Dr. Ann M. Leen Ph.D. Chief Scientific Officer 1977
Ms. Sonia Choi Sr. VP of Corp. Affairs & Investor Relations NA
Mr. Edward Miller J.D. Gen. Counsel & Sec. 1965

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).